Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu minimized the effects of an immune response to the murine single-chain variable fragment component of the CAR, which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu. Severe cytokine release syndrome (sCRS) and grade ≥3 neurotoxicity were observed in 13 and 28% of all patients, respectively. Serum biomarkers, one day after CAR-T cell infusion, correlated with subsequent sCRS and neurotoxicity. Immunotherapy with CD19 CAR-T cells in a defined CD4(+)/CD8(+) ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [36]
In the citing paper
“It is also known that lymphodepletion and the establishment of an optimal homeostatic cytokine environment is critical for robust CAR T-cell expansion and function.4,44,45”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · cited 3×
“We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
BackgroundResultSelf-citation
Research works printed but not linked: 2
- Gordis L Epidemiology 4 Philadelphia Saunders 2008
- Yeh ST Using trapezoidal rule for the area under a curve calculation Proceedings of the Twenty-Seventh Annual SAS User Group International (SUGI) Conference. Paper 229–27 2002
Cited by
Items 501–600 of 999
Mohty, M., Duléry, R., Gauthier, J., Malard, F., Brissot, É., Aljurf, M. D., Bazarbachi, A. A., Chabannon, C., Kharfan‐Dabaja, M. A., Savani, B. N., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0892-7 · Cited by 31
“Therefore, R-CHOP * Mohamad Mohty mohamad.mohty@inserm.fr 1 Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne Université, INSERM UMRs 938, Paris, France 2 Clinical Research Division, Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA…”
InfluentialAmatangelo, M. D., Flynt, E., Stong, N., Ray, P. R., Oekelen, O. V., Wang, M., Ortiz, M., Maciag, P., Peluso, T., Parekh, S. S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101571 · Cited by 26
Atanackovic, D., Luetkens, T., Schneider, D., Hu, P., Wang, X., Shetty, A. C., Tallon, L. J., Patel, I., Singh, R., Gebru, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60980-2 · Cited by 29
Li, W., Wu, L., Huang, C., Liu, R., Li, Z., Liu, L., & Shan, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4502 · Cited by 27
“For patients with moderate to severe CRS, tocilizumab or chimeric anti-IL-6 mAb cetuximab has become the first-choice treatment (10).”
BackgroundTargeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy
Godwin, C. D., Laszlo, G. S., Fiorenza, S., Garling, E. E., Phi, T.-D., Bates, O. M., Correnti, C., Hoffstrom, B. G., Lunn-Halbert, M. C., Humbert, O., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01160-1 · Cited by 22
Guo, J., He, S., Zhu, Y., Yu, W., Yang, D., & Zhao, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.775599 · Cited by 24
Kast, J., Nozohouri, S., Zhou, D., Yago, M. R., Chen, P., Ahamadi, M., Dutta, S., & Upreti, V. V. (2022) · Clinical and Translational Science · doi:10.1111/cts.13349 · Cited by 24
Dupouy, S., Marchiq, I., Derippe, T., Almena-Carrasco, M., Jóźwik, A., Fouliard, S., Adimy, Y., Geronimi, J., Graham, C., Jain, N., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0175 · Cited by 23
“The clinical efficacy of autologous CAR-T cells in patients with B-ALL was shown to positively correlate with higher peak expansion, exposure, and persistence in responder patients as compared with nonresponders (1, 2, 16, 17, 21, 32–34).”
Chen, L., Gong, W., Li, M.-H., Zhou, H., Xu, M., Qian, C., Kang, L., Xu, N., Zhou, Y., Qiao, M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009072 · Cited by 25
“Furthermore, the endogenous immune response against murine CAR may also contribute to the declining CAR T-cell expansion as evidenced by prior studies.(29,30) Although this could be mitigated using an FC (fludarabine + cyclophosphamide) lymphodepletion regimen in our study, the development of humanized single-chain va…”
Pérez-Amill, L., Bataller, Á., Delgado, J., Esteve, J., Juan, M., & Klein-González, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260470 · Cited by 29
Hodge, R., Narayanavari, S. A., Izsvák, Z., & Ivics, Z. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.130 · Cited by 23
“100–106 Many consider this a major medical breakthrough, given the advanced stage of the disease and the failure of conventional treatments in many of the patients included in these clinical trials.”
The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy
Wu, H., & Cao, C. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely011 · Cited by 27
Martens, A. W. J., Janssen, S. R., Derks, I. A. M., Adams, H., Izhak, L., van Kampen, R. J. W., Tonino, S. H., Eldering, E., van der Windt, G. J. W., & Kater, A. P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000218 · Cited by 28
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
Vonberg, F. W., Malik, I., O'Reilly, M. A., Hyare, H., Carr, A. S., & Roddie, C. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-333924 · Cited by 26
Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy
Patel, K. J., Siraj, S., Smith, C., Nair, M. P., Vishwanatha, J. K., & Basha, R. M. (2019) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2019031417 · Cited by 23
Xiang, X., He, Q., Ou, Y., Wang, W., & Wu, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.544754 · Cited by 24
“Subgroup analysis of ORR by age showed that, in patients with mean age ≤55 years, the ORR was higher than in those with >55 years (98.01% vs. 82.58%, interaction p 0.0081).”
ResultInfluentialWang, Y., Zu, C., Teng, X., Yang, L., Zhang, M., Hong, R., Zhao, H., Cui, J., Xu, H., Hongsheng, A. C., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000391 · Cited by 27
Lapidus, A. H., Anderson, M. A., Harrison, S. J., Dickinson, M. J., Kalinčík, T., & Lasocki, A. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2074990 · Cited by 22
Enhanced human T cell expansion with inverse opal hydrogels
Santos, F., Valderas-Gutiérrez, J., del Río, E. P., Castellote‐Borrell, M., Rodríguez, X. R., Veciana, J., Ratera, I., & Guasch, J. (2022) · Biomaterials Science · doi:10.1039/d2bm00486k · Cited by 22
Emerging frontiers in immuno- and gene therapy for cancer
Gustafson, M. P., Ligon, J. A., Bersenev, A., McCann, C. D., Shah, N. N., & Hanley, P. J. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.10.002 · Cited by 24
Controlling therapeutic protein expression via inhalation of a butter flavor molecule
Bertschi, A., Stefanov, B., Xue, S., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1256 · Cited by 22
“There have been major advances in cell-based therapies in recent years, with several engineered T cell therapies approved to treat blood cancers, and many more in the pipeline (30–34).”
CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
Prinzing, B. L., Gottschalk, S. M., & Krenciute, G. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1451749 · Cited by 22
“However, this has not translated in significant differences in clinical outcome.[2-12] A recent preclinical study directly comparing CD19.”
BackgroundResultCancer immune therapy for lymphoid malignancies: recent advances
Klausen, U., Jørgensen, N. G. D., Grauslund, J. H., Holmström, M. O., & Andersen, M. H. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0696-7 · Cited by 24
Management of T-Cell Engaging Immunotherapy Complications
Varadarajan, I., & Lee, D. W. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000377 · Cited by 23
Zheng, X., Zhang, X.-Y., Dong, Q., Chen, F., Yang, S., & Li, W. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000568 · Cited by 23
Oncologic Emergencies: Immune-Based Cancer Therapies and Complications
Long, B., Brem, E. A., & Koyfman, A. (2020) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2020.1.45898 · Cited by 23
Füchsl, F., & Krackhardt, A. M. (2022) · Cells · doi:10.3390/cells11030410 · Cited by 25
Chimeric antigen receptor T-cell therapy in autoimmune diseases
Liu, J., Yan, Z., & Hai, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1492552 · Cited by 23
The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.
Lulla, P., Hill, L. C., Ramos, C. A., & Heslop, H. E. (2018) · PubMed · Cited by 24
Hammill, J. A., Kwiecień, J. M., Dvorkin‐Gheva, A., Lau, V. W. C., Baker, C. L., Wu, Y., Bezverbnaya, K., Aarts, C. W., Heslen, C. W., Denisova, G. F., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.04.001 · Cited by 21
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
Zhylko, A., Winiarska, M., & Graczyk‐Jarzynka, A. (2020) · Cancers · doi:10.3390/cancers12082030 · Cited by 22
“The first CAR-T cell therapy with a defined CD4/CD8 ratio [15,16] appeared to be applicable even in patients with severe leukopenia and is currently under the FDA approval process.”
BackgroundPeraro, L., Bourne, C. M., Dacek, M. M., Akalin, E., Park, J. H., Smith, E. L., & Scheinberg, D. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.022 · Cited by 20
Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer
Ferrer, G., Álvarez‐Errico, D., & Esteller, M. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac088 · Cited by 24
“The incidence of ICANS was associated with a high pretreatment disease burden, a rate of CAR-T cell expansion, higher levels of proinflammatory cytokines, and endothelial markers that can be used as predictors and for personalized monitoring (93,117).”
Neurological adverse effects of chimeric antigen receptor T-cell therapy
Saleki, K., Mohamadi, M. H., Alijanizadeh, P., & Rezaei, N. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2248390 · Cited by 23
“Other features include aphasia, disorientation, confusion, tremors, and somnolence [13,14,18,90–94].”
BackgroundApplication of Genome Editing Techniques in Immunology
Zych, A. O., Bajor, M., & Zagożdżon, R. (2018) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-018-0504-z · Cited by 26
“Anti-CD19 CAR has already been reported to possess a potent anti-tumor activity in B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia or chronic lymphocytic leukemia patients (Turtle et al. 2016).”
BackgroundNovel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia
Prommersberger, S., Jetani, H., Danhof, S., et al. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.006 · Cited by 21
Chu, Y., Gardenswartz, A., Termuhlen, A. M., & Cairo, M. S. (2019) · British Journal of Haematology · doi:10.1111/bjh.15753 · Cited by 24
The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies
Cao, J., Gao, W., You, J., Wu, L.-H., Liu, J., & Wang, Z.-X. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.04.005 · Cited by 25
Xu, Y., Morales, A. J., Cargill, M. J., Towlerton, A. M. H., Coffey, D. G., Warren, E. H., & Tykodi, S. S. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02419-4 · Cited by 23
“The recent clinical success of engineered T-cells expressing CARs specific for CD19 achieving complete remissions of refractory acute lymphocytic leukemia [14] and non-Hodgkin lymphoma [15] has created intense interest to extend engineered T-cells as a therapeutic modality to solid tumor targets.”
BackgroundAnti-CD19 CAR-T cells: Digging in the dark side of the golden therapy
Bouziana, S. D., & Bouzianas, D. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103096 · Cited by 21
Schubert, M., Kunz, A. B., Schmitt, A., Neuber, B., Wang, L., Hückelhoven‐Krauss, A., Langner, S., Michels, B., Wick, A., Daniel, V., et al. (2020) · Cancers · doi:10.3390/cancers12102820 · Cited by 21
Sun, Z., Xun, R., Liu, M., Wu, X., & Qu, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.646450 · Cited by 20
“Eligibility Criteria Studies that met the following criteria were considered for inclusion: (1) All types of clinical studies, including controlled trial, single-arm trial, retrospective study and prospective study; (2) Patients treated with Axi-cel for relapsed or refractory large B-cell lymphoma (LBCL); (3) Some pat…”
MethodHuman induced-T-to-natural killer cells have potent anti-tumour activities
Jiang, Z., Qin, L., Tang, Y., Liao, R. J., Shi, J., He, B., Li, S., Zheng, D., Cui, Y., Wu, Q., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00358-4 · Cited by 20
“04 × 106 ITNKs per kg of body weight after cyclophosphamide (Cy) and/or fludarabine (Flu) lymphodepletion [86] (Table 1).”
BackgroundChimeric antigen receptor T-cell therapy for multiple myeloma
Wang, Z., Chen, C., Wang, L., Jia, Y., & Qin, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050522 · Cited by 24
“Further, those who are treated with a defined ratio (1:1) of CD4/CD8 CAR-T cells, were monitored with more potent T cell expansion and fewer toxicities in vivo (128, 129).”
BackgroundSarén, T., Ramachandran, M., Gammelgård, G., Lövgren, T., Mirabello, C., Björklund, Å. K., Wikstrom, K. I., Hashemi, J., Freyhult, E., Ahlström, H. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0178 · Cited by 19
“Furthermore, we observed a low response rate despite dual CAR-T infusion in a majority of the patients as observed in other studies (4, 45).”
Practical considerations for chimeric antigen receptor design and delivery
Oldham, R. A. A., & Medin, J. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1339687 · Cited by 22
Wang, H., Du, X., Chen, W., et al. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2017.11.028 · Cited by 20
Echeverry, G., Fischer, G. W., & Mead, E. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004201 · Cited by 21
Hematopoietic Stem Cell Approaches to Cancer
Adair, J. E., Kubek, S., & Kiem, H. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.012 · Cited by 20
Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma
Avanzi, M. P., & Brentjens, R. J. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7045 · Cited by 20
Mochel, J. P., Ekker, S. C., Johannes, C. M., Jergens, A. E., Allenspach, K., Bourgois‐Mochel, A., Knouse, M., Benzekry, S., Wierson, W. A., LeBlanc, A. K., et al. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0322-1 · Cited by 25
Miller, C. P., Fung, M., Jaeger-Ruckstuhl, C. A., Xu, Y., Warren, E. H., Akilesh, S., & Tykodi, S. S. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100948 · Cited by 19
Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review
Zhang, Y., & Han, W. (2025) · Clinical Cancer Bulletin · doi:10.1007/s44272-025-00044-0 · Cited by 25
Pharmacology of Chimeric Antigen Receptor–Modified T Cells
Song, E. Z., & Milone, M. C. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031720-102211 · Cited by 25
El-Khazragy, N. N., Ghozy, S. A., Emad, P., Mourad, M., Razza, D., Farouk, Y. K., Mohamed, N. A., Ahmed, M. K., Youssef, T., Bahnasawy, Y. M., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0181 · Cited by 21
Dholaria, B., Savani, B. N., Huang, X., Nagler, A., Perales, M., & Mohty, M. (2021) · British Journal of Haematology · doi:10.1111/bjh.17460 · Cited by 20
“A higher proportion of stem cell memory cells (CCR7+ CD45RA+ CD8+ CAR T cells) in the infused product was associated with better ORR and durable remissions after axi-cel.66 Few other studies using CD19, 4-1BB co-stimulatory CAR T cells have reported a similar positive correlation between peak CAR T expansion and ORR.5…”
ResultA Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells**
Cao, W., Geng, Z. Z., Wang, N., Pan, Q., Guo, S., Xu, S., Zhou, J., & Liu, W. R. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109550 · Cited by 21
The case for CAR T-cell therapy in follicular lymphomas
Bishop, M. R. (2019) · Blood · doi:10.1182/blood.2019001843 · Cited by 18
Mohty, R., & Gauthier, J. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01420-9 · Cited by 20
Halford, Z., Anderson, M. K., & Bennett, L. L. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020944233 · Cited by 18
Yagyu, S., Mochizuki, H., Yamashima, K., Kubo, H., Saito, S., Tanaka, M., Sakamoto, K., Shimoi, A., & Nakazawa, Y. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1291 · Cited by 18
“Non-myeloablative conditioning is widely accepted as a safer strategy used for immunosuppression than conventional myeloablative conditioning, and lymphodepletion with FDR and CPA before CAR-T cell infusion is also considered to increase the persistence of CAR-T cells and antitumor efficacy.(17) Considering that exper…”
ResultExpanding the role of interventional oncology for advancing precision immunotherapy of solid tumors
Kimura, Y., Ghosn, M., Cheema, W., Adusumilli, P. S., Solomon, S. B., & Srimathveeralli, G. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.018 · Cited by 21
“CAR T cell activity is currently monitored by detecting CAR T cells in peripheral venous blood sampled from upper limbs and in biopsy samples from local tumor sites.(145) These clinical samples can be processed and analyzed with cytokine profile, flow cytometry, qPCR, or RNA sequencing (RNA-seq).”
BackgroundMethodCAR-T-Cell Therapy: Present Progress and Future strategies
Abbasi, M. H., Riaz, A., Khawar, M. B., Farooq, A., Majid, A., & Sheikh, N. (2022) · Biomedical Research and Therapy · doi:10.15419/bmrat.v9i2.726 · Cited by 19
He, P., Liu, H., Zimdahl, B., Wang, J., Luo, M., Chang, Q., Tian, F., Fan, N., Yu, D., Liu, H., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04132-9 · Cited by 23
EEG-based grading of immune effector cell-associated neurotoxicity syndrome
Jones, D. K., Eckhardt, C. A., Sun, H., Tesh, R. A., Malik, P., Quadri, S. A., Firme, M. S., van Sleuwen, M., Jain, A., Fan, Z., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24010-1 · Cited by 21
Martin, Y. S., Franz, J. K., Agha, M., & Lazarus, H. M. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101095 · Cited by 21
Tennant, M. D., New, C., Ferreira, L. M. R., & O’Neil, R. T. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.015 · Cited by 17
Montagna, E., de Campos, N. S. P., Porto, V. A., da Silva, G. C. P., & Suarez, E. R. (2024) · BMC Cancer · doi:10.1186/s12885-024-12651-6 · Cited by 22
“19, 20 and 21, respectively).”
CAR T cell immunotherapy in hematology and beyond
Rössig, C. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.09.016 · Cited by 22
Zeng, D., Desai, A. P., Yan, F., Gong, T., Ye, H., Ahmed, M., Nomie, K. J., Romaguera, J. E., Champlin, R. E., Li, S., et al. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000427 · Cited by 20
Chávez, J. C., Jain, M. D., & Kharfan‐Dabaja, M. A. (2019) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2019.05.005 · Cited by 18
Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma
Cahill, K. E., Leukam, M. J., & Riedell, P. A. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1691201 · Cited by 19
Improving CAR T-cells: The next generation
Marple, A., Bonifant, C. L., & Shah, N. N. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.002 · Cited by 20
Keratoconus Detection Using the Fusion Features of Anterior and Lateral Segment Photographed Images
Daud, M. M., Zaki, W. M. D. W., Hussain, A., et al. (2020) · IEEE Access · doi:10.1109/access.2020.3012583 · Cited by 18
Neurological complications of cancer immunotherapy (CAR T cells)
Rubin, D. B., & Vaitkevicius, H. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117405 · Cited by 20
Havard, R., & Stephens, D. M. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0482-6 · Cited by 18
Wang, L. (2021) · Current Research in Translational Medicine · doi:10.1016/j.retram.2021.103320 · Cited by 18
Derippe, T., Fouliard, S., Marchiq, I., Dupouy, S., Almena-Carrasco, M., Geronimi, J., Declèves, X., Chenel, M., & Mager, D. E. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0176 · Cited by 21
Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
Chen, X., Li, P., Tian, B., & Kang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1079181 · Cited by 20
Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies
Salas‐Benito, D., Berger, T. R., & Maus, M. V. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-012235 · Cited by 18
Sakunrangsit, N., Khuisangeam, N., Inthanachai, T., Yodsurang, V., Taechawattananant, P., Suppipat, K., & Tawinwung, S. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03685-7 · Cited by 19
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma
Morabito, F., Martino, E. A., Nizzoli, M. E., Talami, A., Pozzi, S., Martino, M. V., Neri, A., & Gentile, M. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14335 · Cited by 21
“This generation also focused on enhancing survival and cytotoxicity by targeting T-cell suppressor signaling molecules such as PD-1 and CTLA4, thereby broadening CAR-T applicability [48].”
InfluentialReprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Perales, M., Kebriaei, P., Kean, L. S., & Sadelain, M. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.789 · Cited by 18
Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors
Morgan, M. A., & Schambach, A. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.251 · Cited by 18
The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma
Dong, Y., Ding, Y.-M., Guo, W., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s175516 · Cited by 17
“CDl9 is specifically expressed in B cells, at all stages of development, differentiation, and malignancies, but is absent from hematopoietic stem cells and other cells.(11) There are more than 20 clinical trials which are being carried out using CDl9-CAR T-cells in the treatment of hematological malignancies, includin…”
BackgroundCutmore, L. C., Brown, N. F., Raj, D., Chauduri, S., Wang, P., Maher, J. F., Wang, Y., Lemoine, N. R., & Marshall, J. F. (2020) · Pancreatology · doi:10.1016/j.pan.2020.02.006 · Cited by 22
Haran, K. P., Lockhart, A., Xiong, A., Radaelli, E., Savickas, P., Posey, A. D., & Mason, N. J. (2020) · Veterinary Pathology · doi:10.1177/0300985819900352 · Cited by 20
Su, T., Ying, Z., Lu, X., He, T., Song, Y., Wang, X., Ping, L., Xie, Y., Tu, M., Liu, G., et al. (2020) · Cryobiology · doi:10.1016/j.cryobiol.2020.07.009 · Cited by 17
Wang, N., Meng, Y., Wu, Y., He, J., & Liu, F. (2021) · Immunotherapy · doi:10.2217/imt-2020-0221 · Cited by 16
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
Xu, Y., Miller, C. P., Warren, E. H., & Tykodi, S. S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1870846 · Cited by 18
Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
Khurana, A., & Lin, Y. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00920-6 · Cited by 17
Genetic Modification of T Cells with Chimeric Antigen Receptors: A Laboratory Manual
Golumba-Nagy, V., Kuehle, J., & Abken, H. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.083 · Cited by 18
Maloney, E. J., Khokhlova, T. D., Pillarisetty, V. G., Schade, G. R., Repasky, E. A., Wang, Y.-N., Giuliani, L., Primavera, M., & Hwang, J. H. (2017) · International Reviews of Immunology · doi:10.1080/08830185.2017.1363199 · Cited by 17
Kimmel, G. J., Locke, F. L., & Altrock, P. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/717074 · Cited by 17
Clinical experience of CAR T cells for multiple myeloma
Simmons, G. L., Satta, T., & Puglianini, O. A. C. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101306 · Cited by 17
Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans
Ruella, M., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.005 · Cited by 17
BCMA CAR T cells: the winding path to success
Borrello, I., & Imus, P. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128372 · Cited by 15
Yan, L., Shang, J., Shi, X., Kang, H., Liu, W., Xu, N., Liu, Y., Chen, G., Kang, L., Gong, F., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25664 · Cited by 18
“In 2017, the United States Food and Drug Administration approved CD19-targeted CART cells (CARTs) as a salvage treatment for recurrent and/or refractory patients with B cell malignancies.(2,3) In recent years, several CART clinical trials for multiple myeloma (MM) conducted worldwide have shown good clinical response,…”
BackgroundSafety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
Riedell, P. A., & Bishop, M. R. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720902899 · Cited by 19
Prospects to Improve Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Jin, C., Yu, D., & Essand, M. (2016) · Immunotherapy · doi:10.2217/imt-2016-0125 · Cited by 17
Metadata
- Authors
- Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Corresponding author
- Turtle, Cameron J.
- Riddell, Stanley R.
- Maloney, David G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra116-355ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5045301
- OpenAlex
- W2509364267
- Semantic Scholar
- af93b35d4d1ed32f3de2e434b4049004928a60bc
- Cited by
- 1,016
- References
- 38
- Citations by year
- 2026: 37 · 2025: 60 · 2024: 101 · 2023: 78 · 2022: 113 · 2021: 120 · 2020: 153 · 2019: 139 · 2018: 121 · 2017: 85 · 2016: 6
- FWCI
- 63.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA136551)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK56465)
- NCI (P30 CA15704)
- Life Science Discovery Fund
- Bezos Family Foundation
- Juno Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, non-Hodgkin lymphoma, B-cell lymphoma, CD4/CD8 ratio, lymphocyte depletion, cyclophosphamide, fludarabine, cytokine release syndrome, neurotoxicity, serum biomarkers, CAR T cell persistence, relapsed/refractory lymphoma
- MeSH terms
- Adult, Aged, Cyclophosphamide, Female, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Receptors, Antigen, T-Cell, Syndrome, Biomarkers, Tumor, Vidarabine, CD4-Positive T-Lymphocytes, Lymphocyte Subsets, Treatment Outcome, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.